BMY Stock Dips Following Third-Quarter Earnings Beat – Investor’s Business Daily
Drug giants Bristol-Myers Squibb (BMY) and Celgene (CELG) topped third-quarter estimates Thursday, leading BMY stock to break out even as sales of its cancer treatment Opdivo braked.
XIn morning trading on the stock market today, BMY stock advanced 1.6%, nea…
